finnish national guideline for chronic obstructive pulmonary disease (copd) (Duodecim Medical Publications)
Structured Review

Finnish National Guideline For Chronic Obstructive Pulmonary Disease (Copd), supplied by Duodecim Medical Publications, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/finnish+national+guideline+for+chronic+obstructive+pulmonary+disease+(copd)/finnish+national+guideline+for+chronic+obstructive+pulmonary+disease++copd+/pmc04409821-35-17-4
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines"
Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines
Journal: Basic & Clinical Pharmacology & Toxicology
doi: 10.1111/bcpt.12366
Figure Legend Snippet: Classification of the severity of obstruction and the clinical severity of chronic obstructive pulmonary disease (COPD)
Techniques Used:
Figure Legend Snippet: Aims of the pharmacotherapy of chronic obstructive pulmonary disease (COPD) and principles for the evaluation whether to continue or discontinue the current medication.
Techniques Used:
Figure Legend Snippet: Pharmacological compounds used in the therapy of chronic obstructive pulmonary disease
Techniques Used:
Figure Legend Snippet: Effects of smoking cessation, exercise and various pharmacotherapies in the treatment of chronic obstructive pulmonary disease (COPD)
Techniques Used: Biomarker Discovery
Figure Legend Snippet: The principles of diagnostics and phenotype-specific therapy of chronic obstructive pulmonary disease (COPD). Of note, the current indication for the use of different fixed combinations of inhaled glucocorticoid ICS and long-acting β 2 -agonist (LABA) in COPD is frequent exacerbations despite the use of appropriate bronchodilator therapy, but the FEV 1 ranges from <50% predicted (budesonide–formoterol, beclomethasone dipropionate–formoterol) to <60% predicted (fluticasone propionate–salmeterol) and to <70% predicted (fluticasone furoate–vilanterol).
Techniques Used:
Figure Legend Snippet: The principles of combining drugs used to treat chronic obstructive pulmonary disease (COPD). The general rule of drug therapy of COPD is that two drugs belonging to the same group or having similar mechanism of action should not be combined. The exception to this rule is the simultaneous use of short- and long-acting β 2 -agonists that is allowed and often is meaningful
Techniques Used: Medications